论文部分内容阅读
目的:观察苦参素联合阿德福韦酯(ADV)治疗慢性乙型肝炎的临床疗效。方法:85例慢性乙型肝炎患者随机分为治疗组42例与ADV组43例,两组均应用阿德福韦酯片10mg/d,治疗组前24周同时给予苦参素胶囊200mg,po,tid。疗程48周。完成12周、24周和48周治疗时,检测血清HBV DNA水平、乙型肝炎病毒标志物及肝功能变化。结果:治疗组患者在治疗12周、24周和48周时HBV DNA阴转率为:19.0%、57.1%和66.7%高于ADV组的7.0%、34.9%和44.2%,两组比较差异有统计学意义(P<0.01)。在治疗12周和24周时HBeAg阴转率治疗组为:19.0%、35.7%亦高于ADV组的7.0%、16.3%,差异均有统计学意义(P<0.01)。治疗组总有效率在治疗结束时为:69.0%,高于ADV组同期的46.5%。差异有统计学意义(P<0.01)。结论:阿德福韦酯联合苦参素优于单用阿德福韦酯治疗慢性乙型肝炎。
Objective: To observe the curative effect of oxymatrine combined with adefovir dipivoxil on chronic hepatitis B. Methods: Eighty-five patients with chronic hepatitis B were randomly divided into treatment group (42 cases) and ADV group (43 cases). Adefovir dipivoxil tablets (10 mg / d) were given to both groups. Oxymatrine capsules (200 mg) , tid. Treatment for 48 weeks. Serum HBV DNA levels, hepatitis B virus markers, and changes in liver function were measured at 12, 24, and 48 weeks of treatment. Results: The negative conversion rates of HBV DNA in treatment group were 19.0%, 57.1% and 66.7% at 12, 24 and 48 weeks of treatment, respectively, which were 7.0%, 34.9% and 44.2% respectively in ADV group Statistical significance (P <0.01). At 12 and 24 weeks of treatment, HBeAg negative conversion rate was 19.0% in the treatment group and 35.7% in the treatment group, which was also significantly higher than 7.0% and 16.3% in the ADV group (P <0.01). The total effective rate in the treatment group was 69.0% at the end of the treatment, which was 46.5% higher than that in the ADV group. The difference was statistically significant (P <0.01). Conclusions: Adefovir dipivoxil combined with oxymatrine is superior to adefovir dipivoxil alone in the treatment of chronic hepatitis B.